{"filings":[{"id":554838,"accession_number":"0001193125-26-232631","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2026-05-20T20:18:43+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biodesix shareholders elect directors, approve say-on-pay, ratify KPMG at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Jean Franchi (6.19M for, 0 against, 721.8K abstain) and Hany Massarany (6.85M for, 0 against, 66.2K abstain) as Class III directors until 2029.","Non-binding advisory vote on named executive officer compensation passed: 6.62M for, 283.5K against, 11.6K abstain.","Stockholders approved 'one year' frequency for future say-on-pay votes (6.11M for one year, 777.4K for three years).","Ratified KPMG LLP as independent auditor for 2026: 8.70M for, 59 against, 2,429 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92893,"accession_number":"0001193125-26-203936","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q1 revenue $25.6M (+42% YoY); raises FY 2026 revenue guidance to $108-114M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $25.6M, +42% YoY; Diagnostic Testing $22.3M (+37%), Development Services $3.3M (+99%).","Test volumes up 29% to 17,800; average revenue per test improved on expanded payer coverage and RCM enhancements.","Gross margin 82% (excl. one-time $0.4M recovery), up 300 bps YoY; net loss $7.8M (improved 30%); Adj. EBITDA loss $4.1M (improved 35%).","FY 2026 revenue guidance raised to $108-114M (from $106-112M), midpoint implies 25% growth; expects continued Adj. EBITDA improvement.","Cash $25.6M, up 35% from Dec 2025; includes $16.8M ATM net proceeds, partially offset by Q1 cash outflows."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":25555000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104096,"accession_number":"0001193125-26-076521","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q4 revenue $28.8M (+41% YoY), first-ever positive Adj EBITDA $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $28.8M (+41% YoY), gross margin 83% (up 400bps), net loss improved 52% to $4.0M.","Diagnostic test revenue $25.1M (+46% YoY), volumes 18,000 tests (+23%), average rev per test increased.","FY2025 total revenue $88.5M, above raised guidance of $84-86M; FY2026 guidance $106-112M (+23% mid-point).","First-ever positive Adj EBITDA of $0.5M in Q4; FY2025 Adj EBITDA loss $17.5M improved 21% YoY.","Post-quarter: amended Perceptive term loan to Nov 2028, raised $14.7M via ATM; pro forma cash $33.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":88499000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104095,"accession_number":"0001193125-26-010114","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K/A","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix prelim Q4 rev $28.8M (+41%), FY rev $88.5M (+24%), affirms positive Adj EBITDA Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Estimated Q4 total revenue $28.8M (+41% YoY); full-year $88.5M (+24% YoY), exceeding raised guidance of $84-86M.","Lung Diagnostics revenue $25.2M in Q4 (+47% YoY), $79.2M FY (+22% YoY); test volumes 18,000 Q4, 62,600 FY.","Development Services revenue $3.6M Q4 (+13% YoY), $9.3M FY (+41% YoY).","Cash $19.0M as of Dec 31, 2025, up 14% from Q3, including $2.3M ATM proceeds; core cash flat.","Management affirms positive Adjusted EBITDA for Q4 2025 based on strong revenue flow-through."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":88499000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120372,"accession_number":"0001193125-25-262508","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q3 revenue $21.8M (+20% YoY); raises FY2025 guidance to $84-86M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $21.8M, up 20% YoY; gross margin 81% (up 400 bps YoY).","Net loss $8.7M, a 15% improvement YoY; Adjusted EBITDA loss $4.6M, improvement of 18%.","Lung diagnostic testing revenue $19.8M (+16% YoY); Development Services $1.9M (+97% YoY).","Raised FY2025 total revenue guidance to $84-86M from prior range.","Cash $16.6M at Sept 30; accounts receivable increase $5.2M due to timing of collections."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":59744000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120371,"accession_number":"0001193125-25-226749","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biodesix regains Nasdaq minimum bid price compliance; matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Sept. 26, 2025 confirming compliance regained.","Common stock closed at $1.00+ for 10 consecutive business days.","Previously disclosed bid price deficiency on March 24, 2025.","No further action required; ongoing listing on Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136946,"accession_number":"0001193125-25-203746","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Biodesix effects 1-for-20 reverse stock split, eliminates Series A preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:20 ratio effective Sep 15, 2025; new CUSIP 09075X207.","No fractional shares issued; cash-in-lieu based on closing price before effective date.","Certificate of Elimination for Series A Non-Voting Convertible Preferred filed Sep 12, 2025.","Stockholder approval obtained May 20, 2025; Board set final ratio on Sep 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136945,"accession_number":"0001193125-25-200766","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biodesix announces 1-for-20 reverse stock split effective Sept 15, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse split ratio 1:20; shares outstanding drop from ~156M to ~8M.","Effective 12:01 a.m. ET Sept 15; split-adjusted trading begins at market open.","CUSIP changes to 09075X207; ticker BDSX unchanged.","Outstanding options, RSUs, and warrants proportionately adjusted; fractional shares paid in cash.","Stockholders approved at May 20, 2025 annual meeting; final ratio set by board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136944,"accession_number":"0001439725-25-000003","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q2 revenue up 12% to $20M; gross margin 80%; reaffirms FY guidance $80-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $20.0M (+12% YoY); Lung Diagnostic $17.9M (+8%), Development Services $2.1M (+53%).","Gross margin 80% (up 150 bps); net loss $11.5M (+6% YoY); Adjusted EBITDA loss $7.2M.","Reaffirms FY2025 revenue guidance $80-85M; aims for Adjusted EBITDA positive in Q4.","Sales team expanded to 74 reps (+21% YoY); primary care ordering up >100%; digital ordering up 63%.","Development services dollars under contract $12.5M (+54% YoY); ALTITUDE trial enrollment complete."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":37976000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154206,"accession_number":"0001193125-25-124047","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biodesix shareholders approve reverse stock split ratio range 1:2 to 1:20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split of common stock at ratio between 1-for-2 and 1-for-20, as determined by board.","KPMG LLP ratified as independent auditor for FY 2025 with 124.9M votes for.","ESPP amended: shares available increased by 1.45M; annual automatic increase cap raised to 3.0M.","Lawrence T. Kennedy Jr. and Matthew Strobeck elected as Class II directors at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154205,"accession_number":"0000950170-25-070292","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q1 revenue $18M (+21% YoY); revises FY2025 guidance to $80-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q1 2025 revenue $18.0M (+21% YoY); diagnostic testing $16.3M (+18%), development services $1.7M (+61%).","Gross margin 79.4% (vs 78.6%); net loss $11.1M (improved 18% YoY); Adjusted EBITDA loss $6.2M (improved 11%).","FY2025 revenue guidance revised to $80-85M due to ~1-quarter delay in sales expansion; still expects Q4 2025 Adj. EBITDA positivity.","Drew $10M Tranche C from Perceptive Advisors loan, pro forma cash $27.6M; warrants exercise price modified to $0.4191/share.","Operating expenses $23.4M (+3% YoY): R&D up $0.9M, SG&A down 1%; non-cash stock comp fell to $1.0M from $2.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":17958000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154204,"accession_number":"0001193125-25-084319","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Biodesix directors resign effective May 20, 2025; Schuler named director emeritus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles Watts, M.D. resigns from Board and Compensation Committee effective at 2025 Annual Meeting (May 20, 2025).","Jack Schuler resigns from Board and Nominating & Corporate Governance Committee, transitions to director emeritus (non-voting advisory role).","Both resignations not due to any disagreement with Company's operations, policies, or practices.","Dr. Watts served since July 2019; Mr. Schuler served since June 2008."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172801,"accession_number":"0000950170-25-046748","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biodesix receives Nasdaq deficiency notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Biodesix on March 24, 2025 that bid price closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until September 22, 2025, to regain compliance with minimum bid price rule.","To cure, closing bid price must be at least $1.00 for 10 consecutive business days before Compliance Date.","If not cured by Sep 22, may be eligible for additional 180-day period on Nasdaq Capital Market if other standards met.","Company may consider reverse stock split to increase bid price; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172800,"accession_number":"0000950170-25-030814","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix FY2024 revenue $71.3M (+45% YoY); guides FY2025 $92-95M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenue $71.3M, up 45% YoY; gross margin 78%, up 5 pts from FY2023.","Lung Diagnostic testing revenue $64.7M (+43% YoY); Biopharma Services $6.6M (+70% YoY).","Net loss $42.9M improved 18%; adjusted EBITDA loss $22.1M improved 32% vs FY2023.","Cash $26.2M at Dec 31, 2024; post-quarter amended term loan to extend $10M Tranche C availability.","FY2025 total revenue guidance $92-95M, representing 29-33% growth over FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172799,"accession_number":"0000950170-25-003717","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix reports FY2024 revenue $71.3M (+45% YoY), exceeds guidance midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $71.3M in FY2024, up 45% YoY; Q4 revenue $20.4M, up 39% YoY.","Lung Diagnostic revenue $64.7M (+43% YoY); test volumes 54,300 (+40% YoY).","Biopharma Services revenue $6.6M (+69% YoY); $12.2M contracted backlog for 2025 (+54%).","Cash and equivalents $26.2M as of Dec 31, 2024.","Results are preliminary and unaudited; Q4 and FY2024 figures subject to final audit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":71323000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189811,"accession_number":"0000950170-24-119791","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q3 2024 revenue up 35% to $18.2M; lung diagnostic revenue grows 40% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $18.2M (+35% YoY); lung diagnostic revenue $17.2M (+40% YoY).","Net loss improved 6% to $10.3M; Adjusted EBITDA loss $5.6M.","Gross profit margin 77.0% vs 76.1% in Q3 2023; test volume 13,900 (+34% YoY).","Reiterated FY 2024 revenue guidance $70M-$72M; targeting Adjusted EBITDA profitability H2 2025.","Presented Nodify XL2/CDT data at CHEST; launched CLARIFY study for diverse patient data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":50894000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206322,"accession_number":"0001193125-24-200857","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biodesix posts updated corporate presentation with no new financial or operational data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation filed under Item 7.01 and available on IR website.","Company describes itself as a blood-based lung diagnostic firm addressing large unmet need.","No specific financial figures, guidance, or clinical updates were disclosed.","Presentation contains no material new information beyond general business description."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206321,"accession_number":"0000950170-24-092722","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q2 revenue up 51% YoY to $17.9M; raises FY2024 guidance to $70-72M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $17.9M, up 51% YoY; Lung Diagnostic $16.5M (+44%), Biopharma Services $1.4M (+228%).","Gross margin 78.4% vs 72.7% Q2 2023; net loss improved 19% to $10.8M; Adjusted EBITDA loss improved 38% to $5.6M.","Raises full-year 2024 revenue guidance to $70-72M from prior $65-68M.","Lung diagnostic test volume 13,900, up 42% YoY and 17% sequentially.","Cash $42.2M at June 30, 2024, including $55M from April stock offering."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":32743000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223423,"accession_number":"0001193125-24-145965","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biodesix shareholders elect three Class I directors and approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jon Faiz Kayyem, Scott Hutton, and John Patience elected as Class I directors with over 79M votes each.","Ratification of KPMG as independent auditor for FY2024 approved (88.3M for, 167K against).","Conversion of Series A Preferred Stock into common stock approved (82.4M for, 5.8K abstain).","Issuance of Series A Preferred Stock to directors/officers approved (82.3M for, 437K against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223422,"accession_number":"0000950170-24-055608","cik":1439725,"company_name":"BIODESIX INC","ticker":"BDSX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biodesix Q1 revenue $14.8M (+64% YoY); 79% gross margin; raises $55M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $14.8M (+64% YoY); Lung Diagnostic revenue $13.8M (+60%) on 11,900 test volume (+57%).","Gross margin 79% vs 65% YoY; net loss improved 27% to $13.6M.","Adjusted EBITDA loss $7.0M, improvement of 48% from $13.4M loss in Q1 2023.","Raised $55M gross proceeds in April 2024 oversubscribed offering; cash $11.5M at Q1 end excluding proceeds.","Reaffirmed 2024 revenue guidance of $65M-$68M; new collaboration with MSKCC for cancer diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":14818000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":156581903.36326805,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}